CLPTClearPoint Neuro, Inc.
Surgical & Medical Instruments & Apparatus
- Revenue
- $37M
- 18% YoY
- Operating margin
- -65.4%
- 4.0% YoY
- EBITDA
- −$23M
- 25% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $5M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired22% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear7% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $16M | $21M | $24M | $31M | $37M | 18% |
| Operating income | −$13M | −$16M | −$22M | −$20M | −$24M | 22% |
| Net income | −$14M | −$16M | −$22M | −$19M | −$26M | 35% |
| Operating cash flow | −$13M | −$16M | −$14M | −$9M | −$24M | 167% |
| Capex | $168K | $253K | $717K | $275K | $522K | 90% |
| Stock-based comp | $2M | $4M | $6M | $7M | $8M | 18% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $2M | 162 | — |
| FY2024 | $3M | $6M | 137 | — |
| FY2023 | $2M | $1M | 43 | — |